MedTrace Logo

Gastroesophageal Varices in Cavernoma

NCT04525768 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-08-25

No results posted yet for this study

Summary

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein thrombosis and portal cavernoma frequently occur in the MPN population and the management of gastroesophageal varices in these patients are sometimes technically difficult. The aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without JAK2 mutation.

Conditions

  • Gastroesophageal Varices
  • Myeloproliferative Neoplasm
  • Portal Caver Cavernoma
  • Portal Hypertension

Interventions

DIAGNOSTIC_TEST

JAK2 mutation test

Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-09-30
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04525768 on ClinicalTrials.gov